1.29

8.49% 0.101

Akari Therapeutics Plc Adr (AKTX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.189

Offen:

$1.16

24-Stunden-Volumen:

11,154

Relative Volume:

0.21

Marktkapitalisierung:

$34.15M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

-3.7058

EPS:

-0.3481

Netto-Cashflow:

1W Leistung:

+12.17%

1M Leistung:

+32.99%

6M Leistung:

-63.46%

1J Leistung:

-50.38%

1-Tages-Spanne:

$1.16

$1.31

1-Wochen-Bereich:

$1.15

$1.31

52-Wochen-Spanne:

$0.90

$4.40

Akari Therapeutics Plc Adr Stock (AKTX) Company Profile

Firmenname

Akari Therapeutics Plc Adr

Sektor

Healthcare (1176)

Branche

Biotechnology (685)

Telefon

(646) 350-0702

Adresse

22 BOSTON WHARF ROAD, BOSTON

Mitarbeiter

Twitter

@AkariTX

Nächster Verdiensttermin

2024-04-29

Neueste SEC-Einreichungen

AKTX's Discussions on Twitter

Vergleichen Sie AKTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AKTX Akari Therapeutics Plc Adr	1.29	34.15M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2019-01-04	Hochstufung	B. Riley FBR	Neutral → Buy
2018-02-08	Eingeleitet	B. Riley FBR, Inc.	Neutral
2017-09-22	Hochstufung	William Blair	Mkt Perform → Outperform
2017-05-31	Hochstufung	Chardan Capital Markets	Sell → Neutral
2017-04-17	Bestätigt	Chardan Capital Markets	Sell
2016-07-11	Eingeleitet	Chardan Capital Markets	Sell

Alle ansehen

Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten

Dec 28, 2024

Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Growth in Short Interest - Defense World

Dec 28, 2024

Dec 18, 2024

Akari Therapeutics appoints new CEO and board member - Investing.com

Dec 18, 2024

Akari Therapeutics names Samir Patel as CEO and adds board member - Investing.com India

Dec 18, 2024

Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan

Dec 18, 2024

Dec 16, 2024

Akari Therapeutics appoints new CFO - Investing.com

Dec 16, 2024

Akari Therapeutics appoints new CFO By Investing.com - Investing.com South Africa

Dec 16, 2024

AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan

Dec 16, 2024

Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan

Dec 16, 2024

Nov 19, 2024

Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan

Nov 19, 2024

Nov 14, 2024

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga

Nov 14, 2024

Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan

Nov 14, 2024

Nov 08, 2024

Akari Therapeutics shareholders approve Peak Bio merger - Investing.com

Nov 08, 2024

Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK

Nov 08, 2024

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan

Nov 08, 2024

Nov 01, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Nov 01, 2024

Oct 15, 2024

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan

Oct 15, 2024

Oct 04, 2024

Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 04, 2024

Sep 18, 2024